This article is more than 5 years old. Information may no longer be current.
New survey aims to identify ways to improve PCSK9 inhibitor prescription process
Click Here to Manage Email Alerts
The National Lipid Association announced the launch of a new survey on the prescription approval process for PCSK9 inhibitors.
The survey, “Challenges in Prescribing PCSK9 Inhibitors,” will collect information on the experience of health care providers regarding the PCSK9 inhibitor prescription approval process, the National Lipid Association announced today.
The survey will be open through the end of September.
According to the release, patients often have trouble accessing PCSK9 inhibitors even when the medication is properly prescribed, so the survey will aim to identify the main barriers to patients receiving the necessary therapy and ways to improve the process.
The results will be shared in upcoming publications and at future scientific meetings, the association stated in the release.
For more information, visit www.lipid.org/survey.